Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: old 'n cranky who wrote (10056)	4/10/2018 10:05:35 PM
From: HardToFind	Read Replies (1) \| Respond to of 12873

Are you suggesting that because a Phase 1 could be done with 30-50 participants that they could run one for every indication because "we wouldn't mind getting some efficacy data on each of the would-be indications early on and relatively inexpensively"? I think 50% of the first Phase I (human toxicity) would not have to be repeated for the second or third indications. So for roughly twice the price they could do three times the indications (if they're ready with pre-clinical data for all three indications, go for it). But they may not have to do it all at once to get the economies of scale. Once Phase I is done for one indication, risk has been reduced and the cost has dropped for the next two, so (if you have the money) why not go for it. I want them to do formal animal tox testing and Phase I for their most advanced indication as soon as possible. I wish that indication was for genital herpes but alas, it appears to be for shingles. I'm lost. What do you expect them to do? Because I expect more of the same....an orchestrated stall. Until I see otherwise, I expect more of the same. (I don't know if it's orchestrated or not, but it has been consistent.)